Loading page content…
Loading page content…
Spot-IT Assay methodology, as part of the delivery and implementation of the ongoing NHS Newborn Blood Spot in-service evaluation (ISE) for Severe Combined Immuno-Deficiency (SCID) in 3 Screening laboratories. This is essential for NHSE's ongoing newborn screening statutory requirement, and directly impacts on patient care. Due to delays arising from administrative and operational circumstances, NHS England awarded this contract to Immunoivd AB commencing 01.10.2025
BidWriter drafts your responses from your company profile, scores them against the marking scheme, and tracks your whole pipeline. Free to start — no card needed.
Start free →